Get the Stockscreener App
4.96
4.64%
0.22
Precision Biosciences Inc stock is traded at $4.96, with a volume of 65,715.
It is up +4.64% in the last 24 hours and up +2.06% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$4.74
Open:
$4.8
24h Volume:
65,715
Relative Volume:
0.27
Market Cap:
$58.46M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-7.5152
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
+5.31%
1M Performance:
+2.06%
6M Performance:
-16.36%
1Y Performance:
-48.97%
1-Day Range:
$4.78
$4.97
1-Week Range:
$4.5362
$4.99
52-Week Range:
$3.61
$11.09
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.96 | 58.35M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
How high can Precision BioSciences Inc. stock go2025 Top Decliners & Proven Capital Preservation Methods - Newser
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Will Precision BioSciences Inc. continue its uptrendGold Moves & AI Driven Stock Movement Reports - Newser
Precision BioSciences Inc.’s volatility index tracking explainedWeekly Profit Report & Reliable Volume Spike Trade Alerts - Newser
Will Precision BioSciences Inc. stock go up soonWeekly Profit Report & Verified Stock Trade Ideas - Newser
Tools to assess Precision BioSciences Inc.’s risk profileJuly 2025 Market Mood & Real-Time Volume Trigger Notifications - Newser
Visual analytics tools that track Precision BioSciences Inc. performanceWeekly Market Outlook & Free Weekly Watchlist of Top Performers - Newser
Published on: 2025-08-19 13:56:05 - Newser
Will breakout in Precision BioSciences Inc. lead to full recovery2025 Retail Activity & High Return Stock Watch Alerts - Newser
Published on: 2025-08-17 21:42:46 - Newser
How Precision BioSciences Inc. stock performs during market volatilityJuly 2025 Drop Watch & Comprehensive Market Scan Insights - Newser
Can momentum traders help lift Precision BioSciences Inc.Market Risk Report & Free Low Drawdown Momentum Trade Ideas - Newser
Can Precision BioSciences Inc. recover in the next quarterMarket Sentiment Review & Safe Swing Trade Setup Alerts - Newser
Why Precision BioSciences Inc. stock attracts strong analyst attentionRisk Management & Fast Moving Market Watchlists - Newser
Precision Biosciences shares fall 1.89% premarket after Tyra Biosciences reports financial results and corporate progress. - AInvest
Precision BioSciences Reports Significant Quarterly Loss - TipRanks
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates - MSN
Applying Elliott Wave Theory to Precision BioSciences Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Is Precision BioSciences Inc. stock entering bullish territorySafe Investment Ideas with Growth Upside - Newser
Precision BioSciences: Q2 Earnings Snapshot - Connecticut Post
DTIL Revenue Drops 99% - AOL.com
Precision BioSciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences Reports Second Quarter 2025 Financial Resu - GuruFocus
TR | OpenAI4o Maintains Precision BioSciences(DTIL.US) With Hold Rating, Maintains Target Price $5 - 富途牛牛
Precision BioSciences Reports Breakthrough: 69% HBV Reduction and FDA Recognition for DMD Program - Stock Titan
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B - Pipelinereview
Positive Outlook for Precision BioSciences Amid Promising Clinical Trial Data and Strategic Advancements - TipRanks
Precision BioSciences Reports Promising Phase 1 Trial Results - TipRanks
Precision BioSciences Announces Phase 1 Safety and Efficacy for - GuruFocus
Precision BioSciences reports positive data for hepatitis B gene therapy By Investing.com - Investing.com Canada
Using R and stats models for Precision BioSciences Inc. forecastingPredictive AI Engine for Smart Investing - Newser
Precision BioSciences announces Phase 1 safety and efficacy for cohort 1, lowest dose level in Eliminate-B, a first-in-human trial of PBGENE-HBV for Chronic Hepatitis B - MarketScreener
Precision BioSciences Inc expected to post a loss of $1.57 a shareEarnings Preview - TradingView
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 - BioSpace
Published on: 2025-08-04 08:00:09 - beatles.ru
Precision BioSciences: A Strategic Play in the Gene Editing Revolution Amid Q2 Momentum and Regulatory Breakthroughs - AInvest
Precision BioSciences Inc. Stock Analysis and ForecastRemarkable growth - Jammu Links News
Is Precision BioSciences Inc. stock overvalued or undervaluedGet exclusive market insights for better trading - Jammu Links News
What institutional investors are buying Precision BioSciences Inc. stockInvest in stocks with long-term growth potential - Jammu Links News
What is Precision BioSciences Inc. company’s growth strategyRealize consistent double-digit growth - Jammu Links News
Does Precision BioSciences Inc. stock perform well during market downturnsCapitalize on high-growth stocks early - Jammu Links News
When is Precision BioSciences Inc. stock expected to show significant growthMaximize profits with strategic stock selection - Jammu Links News
Using data filters to optimize entry into Precision BioSciences Inc.Free Real-Time Market Sentiment Tracking Tool - Newser
What are the latest earnings results for Precision BioSciences Inc.Achieve rapid portfolio appreciation today - Jammu Links News
What catalysts could drive Precision BioSciences Inc. stock higher in 2025Capitalize on high-growth stocks early - Jammu Links News
Is it the right time to buy Precision BioSciences Inc. stockUnprecedented market success - Jammu Links News
Published on: 2025-08-03 13:05:53 - Jammu Links News
What are analysts’ price targets for Precision BioSciences Inc. in the next 12 monthsFind the best stocks for sustainable growth - Jammu Links News
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):